Amalgamated Bank Buys 2,228 Shares of Cencora, Inc. (NYSE:COR)

Amalgamated Bank boosted its position in Cencora, Inc. (NYSE:COR) by 6.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 37,969 shares of the company’s stock after purchasing an additional 2,228 shares during the period. Amalgamated Bank’s holdings in Cencora were worth $8,546,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of COR. Price T Rowe Associates Inc. MD bought a new stake in Cencora during the 1st quarter valued at $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in Cencora in the first quarter worth approximately $1,199,695,000. Boston Partners bought a new position in shares of Cencora during the 1st quarter valued at $1,001,269,000. Capital Research Global Investors bought a new position in shares of Cencora during the first quarter valued at about $650,424,000. Finally, Bessemer Group Inc. purchased a new position in Cencora in the 1st quarter worth approximately $556,245,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of a number of research analyst reports. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Robert W. Baird dropped their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. Finally, Evercore ISI cut their price target on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 15.80% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $245.38 on Thursday. The stock has a 50-day moving average price of $231.57 and a 200 day moving average price of $230.64. The stock has a market capitalization of $48.35 billion, a P/E ratio of 26.64, a P/E/G ratio of 1.49 and a beta of 0.44. Cencora, Inc. has a 12-month low of $191.11 and a 12-month high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.